HC Wainwright Has Bearish Estimate for Balchem Q1 Earnings

Balchem Co. (NASDAQ:BCPC) – Investment analysts at HC Wainwright dropped their Q1 2025 earnings per share estimates for Balchem in a report released on Monday, February 24th. HC Wainwright analyst R. Selvaraju now expects that the basic materials company will post earnings of $0.99 per share for the quarter, down from their previous forecast of $1.06. HC Wainwright has a “Buy” rating and a $190.00 price target on the stock. The consensus estimate for Balchem’s current full-year earnings is $4.64 per share. HC Wainwright also issued estimates for Balchem’s Q2 2025 earnings at $1.03 EPS, Q3 2025 earnings at $1.08 EPS, Q4 2025 earnings at $1.12 EPS, FY2025 earnings at $4.22 EPS, Q1 2026 earnings at $1.13 EPS, Q2 2026 earnings at $1.17 EPS, Q3 2026 earnings at $1.20 EPS and FY2026 earnings at $4.71 EPS.

Balchem (NASDAQ:BCPC) last announced its quarterly earnings data on Friday, February 21st. The basic materials company reported $1.03 earnings per share for the quarter, missing the consensus estimate of $1.11 by ($0.08). The firm had revenue of $240.00 million during the quarter, compared to analyst estimates of $239.96 million. Balchem had a net margin of 13.47% and a return on equity of 11.37%.

Separately, StockNews.com downgraded shares of Balchem from a “buy” rating to a “hold” rating in a report on Tuesday.

Balchem Price Performance

Shares of NASDAQ BCPC opened at $172.69 on Wednesday. Balchem has a twelve month low of $137.69 and a twelve month high of $186.03. The company has a current ratio of 1.99, a quick ratio of 1.16 and a debt-to-equity ratio of 0.19. The firm has a 50-day moving average of $162.13 and a two-hundred day moving average of $169.46. The company has a market capitalization of $5.61 billion, a price-to-earnings ratio of 43.94, a PEG ratio of 4.41 and a beta of 0.69.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in BCPC. Creative Planning lifted its position in shares of Balchem by 33.4% in the 3rd quarter. Creative Planning now owns 9,777 shares of the basic materials company’s stock valued at $1,721,000 after acquiring an additional 2,449 shares in the last quarter. Raymond James & Associates lifted its holdings in shares of Balchem by 7.4% in the third quarter. Raymond James & Associates now owns 54,089 shares of the basic materials company’s stock valued at $9,520,000 after purchasing an additional 3,741 shares in the last quarter. Private Advisor Group LLC acquired a new stake in shares of Balchem in the third quarter worth $220,000. First Trust Direct Indexing L.P. grew its holdings in shares of Balchem by 12.5% during the third quarter. First Trust Direct Indexing L.P. now owns 1,589 shares of the basic materials company’s stock valued at $280,000 after buying an additional 177 shares in the last quarter. Finally, Congress Asset Management Co. raised its position in Balchem by 12.4% during the third quarter. Congress Asset Management Co. now owns 301,440 shares of the basic materials company’s stock valued at $53,053,000 after buying an additional 33,373 shares during the period. 87.91% of the stock is currently owned by institutional investors and hedge funds.

Balchem Increases Dividend

The business also recently announced an annual dividend, which was paid on Friday, January 17th. Stockholders of record on Thursday, December 26th were issued a dividend of $0.87 per share. This represents a dividend yield of 0.4%. This is an increase from Balchem’s previous annual dividend of $0.79. The ex-dividend date of this dividend was Thursday, December 26th. Balchem’s dividend payout ratio is currently 22.14%.

Balchem Company Profile

Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.